Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps
Reviewed 10 sourcesPublished by PepVault
Heartburn and acid reflux on Ozempic, Wegovy, Mounjaro and Zepbound: the four labels' rates against placebo, when it shows up, what helps and when to call.

- Last reviewed
- Sources
- 10
- Questions
- 6
- Compounds
- 2
The short answer
Yes, GLP-1 shots can bring on heartburn and reflux. In the weight trials, reflux affected 4% to 5% on Wegovy and Zepbound against 2% to 3% on placebo, and indigestion 9% to 10% against 3% to 4%. Ozempic's and Mounjaro's diabetes trials saw reflux in 2.5% or less. Wegovy's label says it came mostly while the dose climbed. Smaller meals, an earlier dinner and a raised bed head help.
Evidence: The rates come from the four FDA labels' placebo-controlled trials and one open-label head-to-head trial; the real-world risk and the weight-loss link are observational studies; the guideline's lifestyle steps rest mostly on low-level evidence.

How common is heartburn on Ozempic, Wegovy, Mounjaro and Zepbound?
Heartburn is the burning feeling behind the breastbone when stomach acid rises into the gullet. The labels count it under three names: reflux (gastroesophageal reflux disease, GERD), indigestion (dyspepsia, a sore or overfull upper belly) and burping (eructation). Each cell below is the share of people in the label's trials who reported the effect at least once, on the drug and on placebo, a dummy shot that shows how often it turns up anyway (pepvault.app/glossary/placebo)1234.
| Label and its trials | Reflux | Indigestion | Burping |
|---|---|---|---|
| Ozempic 0.5 and 1 mg, two diabetes trials | 1.9%, 1.5% vs 0%1 | 3.5%, 2.7% vs 1.9%1 | 2.7%, 1.1% vs 0%1 |
| Wegovy 2.4 mg, three weight trials up to 68 weeks | 5% vs 3%2 | 9% vs 3%2 | 7% vs under 1%2 |
| Mounjaro 5, 10 and 15 mg, two diabetes trials | 1.7%, 2.5%, 1.7% vs 0.4%3 | 8%, 8%, 5% vs 3%3 | 3.0%, 2.5%, 3.3% vs 0.4%3 |
| Zepbound 5, 10 and 15 mg, two weight trials up to 72 weeks | 4%, 4%, 5% vs 2%4 | 9%, 9%, 10% vs 4%4 | 4%, 5%, 5% vs 1%4 |
Two patterns stand out. Indigestion is the most common of the three, about twice as common as reflux itself. And the weight labels run higher than the diabetes labels, with higher doses, longer trials and different people; each label warns that rates from one drug's trials cannot be compared directly with another's1234. Wegovy also counts gastritis, an irritated stomach lining that includes reflux gastritis, at 4% against 1%2. On the higher Wegovy 7.2 mg dose, reflux, indigestion and burping are not among the effects the label lists as more common than on 2.4 mg2. Each brand's full label is on its drug page: pepvault.app/drugs/ozempic, /drugs/wegovy, /drugs/mounjaro and /drugs/zepbound.

Is reflux worse on Zepbound or on Wegovy?
Head to head, reflux was less common on tirzepatide, while burping went the other way. SURMOUNT-5 gave 750 adults with obesity, or overweight with a weight-related condition, either tirzepatide (Zepbound's medicine) up to 15 mg or semaglutide (Wegovy's) up to 2.4 mg for 72 weeks, and its registry results count every effect seen in at least 5%5 (pepvault.app/research/tirzepatide-surmount-5-2025):
| Effect | Tirzepatide, 374 people | Semaglutide, 376 people |
|---|---|---|
| Reflux | 23 (6.1%)5 | 40 (10.6%)5 |
| Burping | 37 (9.9%)5 | 29 (7.7%)5 |
| Indigestion | 22 (5.9%)5 | 28 (7.4%)5 |
| Nausea, for scale | 163 (43.6%)5 | 167 (44.4%)5 |
SURMOUNT-5 was open-label (everyone knew which drug they had; pepvault.app/glossary/open-label), had no placebo group and was run by Eli Lilly, Zepbound's maker. The two drugs' wider side-effect comparison is in PepVault's guide to semaglutide vs tirzepatide side effects.
Why do GLP-1s cause heartburn?
Mostly because food stays in the stomach longer. All four labels say these drugs slow gastric emptying, the speed at which the stomach passes food on to the gut1234. A stomach that stays full longer has more to push back up, which fits the fullness, the burping and the burn. The Zepbound label adds that the slowing is largest after the first dose and shrinks with the doses that follow4.
Whether the drugs also change the gullet itself is unsettled. Two recent studies measured it with manometry, a pressure test of the gullet's squeeze: at Duke, 42 people with type 2 diabetes on a GLP-1 and 90 who were not showed no significant difference in motility, nor in reflux on formal reflux testing7, while a Mayo Clinic report linked GLP-1 use with motility abnormalities8.
Outside the trials, a large UK study followed 24,708 UK adults with type 2 diabetes who started a GLP-1 and 89,096 who started an SGLT-2 inhibitor, another diabetes pill. Over three years, a new reflux diagnosis was 27% more likely on the GLP-1, which works out to 0.7 extra diagnoses per 100 people6. Reflux complications were 55% more likely too, but that came to 0.8 extra cases per 1,000 people, rare either way6.
When does GLP-1 heartburn start, and does it go away?
It starts mostly in the dose climb, called titration (pepvault.app/glossary/titration). Wegovy's label says its stomach effects, indigestion, burping and reflux included, were reported most often during dose escalation2. No label or trial table breaks reflux down week by week, so the steps of the climb are the best map of when to expect it. These are the labels' schedules, the weeks when a new dose begins24; Zepbound stops at the maintenance dose chosen (5, 10 or 15 mg), and Mounjaro climbs the same 2.5 mg steps only if more blood-sugar control is needed34:
| Weeks | Wegovy, on its label | Zepbound, on its label |
|---|---|---|
| 1 to 4 | 0.25 mg2 | 2.5 mg4 |
| 5 to 8 | 0.5 mg2 | 5 mg at the earliest4 |
| 9 to 12 | 1 mg2 | 7.5 mg at the earliest4 |
| 13 to 16 | 1.7 mg2 | 10 mg at the earliest4 |
| 17 to 20 | The maintenance dose2 | 12.5 mg at the earliest4 |
| 21 on | The maintenance dose; 7.2 mg at the earliest2 | 15 mg at the earliest4 |
Over the longer run, the weight itself works the other way. In Norway's HUNT study of 29,610 adults surveyed about 11 years apart, people whose BMI fell by more than 3.5 units had about twice the odds of losing their reflux symptoms, and about four times the odds among those on weekly reflux medicine9. That is why weight loss, for people with overweight, is the one strong lifestyle recommendation in the American College of Gastroenterology's reflux guideline10. The common picture, then, is a few rough weeks after a step-up while the weight loss builds.
What helps heartburn on a GLP-1?
The same steps that help reflux in anyone, from the American College of Gastroenterology's 2022 guideline10, fit the slow stomach these drugs make:
- Eat smaller meals: a fuller stomach has more to push back up10.
- Finish dinner two to three hours before you lie down10.
- If heartburn wakes you at night, raise the head of the bed and sleep on your left side; lying on the right side brings more reflux at night10.
- Watch your own triggers. In lab tests, fatty meals, chocolate, peppermint, alcohol and smoking lowered the pressure of the valve at the top of the stomach, while coffee, citrus and spicy food barely changed it but can still sting10.
- Note the week, the dose and the time of day each time it flares, so you and your prescriber can see whether it follows the step-ups.
- Ask a pharmacist or your prescriber about an antacid or an acid reducer if the steps are not enough. None of the four labels names either among its drug interactions, and Wegovy's label found omeprazole did not meaningfully change semaglutide levels from the Wegovy tablet1234.
In PepVault, the GLP-1 check-in on Today has a Heartburn chip you tap once, and the side-effect log keeps your own words with a severity, the compound, the date and a note. Log it in PepVault
Commonly reported: heartburn that is worse at night or after a big or fatty meal, sour or sulphur-tasting burps, and food that seems to sit high under the breastbone, most of it in the days after a dose step and easing as the dose settles. On PepVault's reports pages (pepvault.app/peptides/semaglutide/reviews and /peptides/tirzepatide/reviews), heartburn was named by 2 of the 41 people whose semaglutide reports we read and 2 of the 77 for tirzepatide.
What to eat and drink is its own guide: PepVault's guides to eating on a GLP-1 and coffee on a GLP-1 take it food by food. If heartburn keeps you from eating or holding fluids, a slower climb or a pause at the current dose is a decision for your prescriber; the Wegovy label itself suggests delaying a step by four weeks when a dose is not tolerated2.
When is it not just heartburn?
A few pains can feel like heartburn and are not. The labels name two: pain from the pancreas, which is severe, does not go away and can reach the back, and gallbladder trouble, which brings upper-belly pain with fever, yellow skin or eyes, or pale stools24. Chest pressure or tightness, above all with breathlessness or sweating, is checked for the heart first, and the guideline tests chest pain for reflux only after heart disease is ruled out10. And trouble swallowing or signs of bleeding are reasons the guideline gives for a camera test10.
When to get help Severe belly pain that will not go away, with or without vomiting and sometimes felt in the back, is the labels' sign to stop the shot and call your prescriber right away24.
Everything else on the labels, from nausea to hair loss, is in the side-effect guides for Ozempic and Wegovy and for Mounjaro and Zepbound, and on the semaglutide and tirzepatide side-effect pages (pepvault.app/peptides/semaglutide/side-effects).
Sources
- OZEMPIC (semaglutide) injection prescribing information, DailyMed, version 20, updated June 1, 2026, published June 10, 2026. dailymed.nlm.nih.gov
- WEGOVY (semaglutide) injection and WEGOVY tablets prescribing information, DailyMed, version 19, updated June 18, 2026, published June 30, 2026. dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) injection prescribing information, DailyMed, version 40, updated August 27, 2026, published September 2, 2026. dailymed.nlm.nih.gov
- ZEPBOUND (tirzepatide) injection prescribing information, DailyMed, version 40, updated August 28, 2026, published September 2, 2026. dailymed.nlm.nih.gov
- SURMOUNT-5 (NCT05822830), tirzepatide vs semaglutide in obesity, results posted on ClinicalTrials.gov, sponsor Eli Lilly; published as Aronne LJ et al., N Engl J Med 2025. clinicaltrials.gov
- Noh Y et al. Glucagon-like peptide-1 receptor agonists and risk for gastroesophageal reflux disease in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med. 2025. PubMed 40658955
- Wang AL et al. Esophageal motility patterns are not impacted by glucagon-like peptide-1 receptor agonist use. J Clin Gastroenterol. 2026. PubMed 42133868
- Gala K et al. Glucagon-like peptide-1 receptor agonist use is associated with and may lead to esophageal motility abnormalities. Clin Gastroenterol Hepatol. 2026. PubMed 41213390
- Ness-Jensen E et al. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2013. PubMed 23358462
- Katz PO et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022. PubMed 34807007
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.